AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2019
Jan 10, 2019
31523_dirs_2019-01-10_19fe00e5-4a5d-4bb2-bf32-b26448e9275b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2019-01-02
Reporting Person: Crowley John F (Director, Chairman & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-01-02 | Common Stock | A | 233477 | — | Acquired | 668081 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-01-02 | Stock Options (right to buy) | $10.04 | A | 358126 | Acquired | 2029-01-02 | Common Stock (358126) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 64895 | Indirect |
Footnotes
F1: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.
F2: The Restricted Stock Units will vest in four equal annual installments beginning on January 2, 2020.
F3: These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on the first anniversary of the grant date. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments beginning on the first month thereafter.